Elevated MTA concentrations in MTAP−/− cancer cells provide partial inhibition of PRMT5, which would be enhanced in terms of cancer cell lethality when combined with an inhibitor of PRMT5 directly or with an inhibitor of MAT2A, which supplies SAM for PRMT5. This evidence concerns the gene MAT2A and cancer.